Nevro to Report Third Quarter 2020 Financial Results
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, will announce its Q3 financial results on November 5, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, will announce its Q3 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 1:30 PM PT/4:30 PM ET, accessible via dial-in or webcast. Nevro's Senza spinal cord stimulation system offers innovative non-drug therapies, significantly reducing or eliminating opioid use in over 65% of patients. This event is critical for investors monitoring Nevro's financial performance and future outlook.
Positive
- Innovative products improving chronic pain management.
- Senza system shown to reduce or eliminate opioids in ≥65% of patients.
Negative
- None.
Details
News Market Reaction – NVRO
The recorded move for NVRO in the trading session of this news was -0.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 after the market closes on November 5, 2020.
Management will host a conference call on November 5, 2020 to discuss third quarter 2020 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 6693376. In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investor Relations:
Matt Bacso, CFA
ir@nevro.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-third-quarter-2020-financial-results-301158375.html
SOURCE Nevro Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.